Monte Rosa Therapeutics
GLUE· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +125.9% in FY2025
Markus Warmuth, M.D. is the CEO of Monte Rosa Therapeutics and was paid $5.0M in FY2025 (Dec), up 106%.
Pay$100 in the stock at the end of FY21 → $77
Executives3
See all- 1Markus Warmuth, M.D.Chief Executive OfficerFY2025
- 2Filip Janku, M.D., Ph.D.Chief Medical OfficerFY2025
- 3Phil Nickson, Ph.D.Chief Business and Legal OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allMonte Rosa Therapeutics paid its 3 named executives $8.9M in total in FY2025 (Dec). CEO Markus Warmuth, M.D. was paid $5.0M of that.
| Name | |||
|---|---|---|---|
| Markus Warmuth, M.D.Chief Executive Officer | |||
| Filip Janku, M.D., Ph.D.Chief Medical Officer | |||
| Phil Nickson, Ph.D.Chief Business and Legal Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Monte Rosa Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board4
See all- Andrew Schiff, M.D.Chair · 5 yr on the boardIndependentAudit—Paid as an executive
- Chandra P. Leo, M.D.Director · 5 yr on the boardIndependentAudit—Paid as an executive
- Kimberly L. Blackwell, M.D.Director · 5 yr on the boardIndependentCompensation (Chair)—Paid as an executive
- Anthony Manning, Ph.D.Director · 2 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 29, 2026 | FY2025 |
| Annual report | 10-K | Mar 17, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 25, 2025 | FY2024 |
| Annual report | 10-K | Mar 20, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 14, 2024 | FY2023 |
